Partners4Access To Share Insights On Gene Therapy Access at WODC US 2020
P4A are gold sponsors and are also exhibiting at the event.
P4A's Sophie Schmitz, managing partner; Akshay Kumar, partner; Nicola Allen, associate director and Max Rex, consultant will be speaking at the congress.
On August 26, P4A will be participating in two events. At 4:05 pm, Sophie Schmitz will be moderating the keynote panel on 'Successfully navigating a new era: outlooks on future access to treatments, cures and clinical trials for rare disease patients.'
Nicola Allen and Max Rex will be leading the interactive roundtable on 'Expanded Access Programs (EAP) in Europe: Are they right for your therapy' at 19:10 PM. The discussion will aim to understand the role of EAP in supporting successful orphan drug launches and how to effectively implement them.
On August 27 at 14:20 PM, Sophie Schmitz will be presenting on 'Planning a successful cell and gene therapy launch in Europe in an ever-changing landscape for transformative therapies' under the congress' Pricing & Reimbursement track.
Following the presentation, Akshay Kumar will moderate a panel about 'Articulating the value of curative therapies for pricing and reimbursement'.
For more details and agenda of the event, please visit the WODC website (https://www.terrapinn.com/
WODC organized by Terrapinn brings together a global gathering of over 1500 attendees from 50 countries specializing in orphan drugs, featuring over 300 speakers covering all aspects of orphan drug development, market access, cell and gene therapy, advocacy and rare disease research. For more details, please visit the Terrapinn website here (https://www.terrapinn.com/
Partners4Access are experts in orphan drug, cell and gene therapy access, partnering with the biotechnology industry to support launches worldwide. Our services focus on five key areas: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence.
As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access. Through various media initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please visit P4A's website: www.partners4access.com or email at firstname.lastname@example.org.